Vir Biotechnology Inc (NASDAQ:VIR)’s traded shares stood at 2.22 million during the last session, with the company’s beta value hitting 0.55. At the close of trading, the stock’s price was $10.50, to imply an increase of 2.69% or $0.27 in intraday trading. The VIR share’s 52-week high remains $14.45, putting it -37.62% down since that peak but still an impressive 37.52% since price per share fell to its 52-week low of $6.56. The company has a valuation of $1.45B, with an average of 5.83 million shares in intraday trading volume over the past 10 days and average of 2.10 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Vir Biotechnology Inc (VIR), translating to a mean rating of 1.56. Of 10 analyst(s) looking at the stock, 0 analyst(s) give VIR a Sell rating. 0 of those analysts rate the stock as Overweight while 3 advise Hold as 7 recommend it as a Buy.
Vir Biotechnology Inc (NASDAQ:VIR) trade information
After registering a 2.69% upside in the last session, Vir Biotechnology Inc (VIR) has traded red over the past five days. The 5-day price performance for the stock is 33.08%, and 41.32% over 30 days. With these gigs, the year-to-date price performance is 43.05%. Short interest in Vir Biotechnology Inc (NASDAQ:VIR) saw shorts transact 6.55 million shares and set a 4.51 days time to cover.
The extremes give us $20 and $28 for target low and target high price respectively. As such, VIR has been trading -166.67% off suggested target high and -90.48% from its likely low.
Vir Biotechnology Inc (VIR) estimates and forecasts
Looking at statistics comparing Vir Biotechnology Inc share performance against respective industry, we note that the company has underperformed competitors. Vir Biotechnology Inc (VIR) shares are 2.64% up over the last 6 months, with its year-to-date growth rate lower than industry average at 14.60% against 16.70%.
VIR Dividends
Vir Biotechnology Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Vir Biotechnology Inc (NASDAQ:VIR)’s Major holders
Vir Biotechnology Inc insiders hold 11.90% of total outstanding shares, with institutional holders owning 74.11% of the shares at 84.12% float percentage. In total, 74.11% institutions holds shares in the company, led by SB INVESTMENT ADVISERS (UK) LTD. As of 2024-06-30, the company held over 16.68 million shares (or 12.3329% of shares), all amounting to roughly $148.49 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 16.43 million shares, or about 12.1482% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $146.26 million.
We also have iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Vir Biotechnology Inc (VIR) shares. Going by data provided on Oct 31, 2024 , iShares Core S&P Smallcap ETF holds roughly 5.82 shares. This is just over 4.23% of the total shares, with a market valuation of $61.11 million. Data from the same date shows that the other fund manager holds a little less at 3.46, or 2.51% of the shares, all valued at about 36.34 million.
